Abstract | BACKGROUND: MATERIALS AND METHODS: A total of 52 hypertrophic cardiomyopathy patients were enrolled in the study. Patients were questioned for sudden death risk predictors as outlined in the 2014 European Society of Cardiology guideline. A standardized clinical evaluation was carried out on the basis of previously described prognostic variables to calculate the 5-year risk of SCD. Blood samples were taken from all patients to measure serum galectin-3 levels. A statistical significance level of P < 0.05 was accepted in all tests. RESULTS: We found that there was a significant correlation between the estimated 5-year risk of SCD and serum levels of galectin-3. CONCLUSIONS:
|
Authors | Samim Emet, Mubariz Dadashov, Mehmet Rasih Sonsoz, Mustafa Ozan Cakir, Mustafa Yilmaz, Ali Elitok, Ahmet Kaya Bilge, Fehmi Mercanoglu, Aytac Oncul, Kamil Adalet, Imran Onur |
Journal | The American journal of the medical sciences
(Am J Med Sci)
Vol. 356
Issue 6
Pg. 537-543
(12 2018)
ISSN: 1538-2990 [Electronic] United States |
PMID | 30342718
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Biomarkers
- Blood Proteins
- Galectin 3
- Galectins
- LGALS3 protein, human
|
Topics |
- Adult
- Aged
- Biomarkers
(blood)
- Blood Proteins
- Cardiomyopathy, Hypertrophic
(complications)
- Death, Sudden, Cardiac
(epidemiology)
- Female
- Galectin 3
(blood)
- Galectins
- Humans
- Male
- Middle Aged
- Risk Factors
- Turkey
(epidemiology)
- Young Adult
|